Take a look at the recent financials from #stryker
. Obviously the company isn't overly concerned with the 'expenses' related to its pending lawsuits related to #strykerrejuvenate
as the company anticipate that less than $400M should do the trick to get these cases wrapped up.
"However, management announced that the Rejuvenate and ABG II hip products
recall in June 2012 has resulted in a fourth-quarter charge of $174 million before taxes ($133 million net of taxes) or 35 cents per share. However, this is regarded as a one-time expense by the company and is excluded from the adjusted earnings per share. Stryker expects total expenses of $190 million to $390 million for patient testing and treatment, lawsuits and insurance payments related to the product recall.